In early 2002, the FDA and Health Canada issued federal advisories that people should discontinue taking the herbal antianxiolitic Piper methysticum until further information regarding its safety and potential for liver damage was determined. A group of researchers conducted a field study 2 months following the advisories in Toronto, Canada, to determine whether or not P. methysticum continued to be recommended to consumers at retail health-food stores. Eight participants asked employees at all stores what was recommended for anxiety and whether the products were safe. Twenty-two of 34 stores recommended P. methysticum, nine of which mentioned safety concerns.